Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Research Collaboration by Chugai, the University of Tokyo and RIKEN on Functional Genome Database Published in Cell

05/05/2021 | 10:35pm EDT

Research Collaboration by Chugai, the University of Tokyo and RIKEN

on Functional Genome Database Published in Cell

  • Research collaboration by Chugai, the University of Tokyo, and RIKEN published online in the U.S. scientific magazine Cell
  • Created the world's largest functional genome database ImmuNexUT and analyzed the relationship between the onset of immune-mediated diseases and the genomic polymorphisms based on Asian genomic data

TOKYO, May 6, 2021 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced that the research collaboration by Chugai (Forerunner Pharma Research), Department of Allergy and Rheumatology at the University of Tokyo Hospital, and RIKEN on a functional genome database was published online in the U.S. scientific journal Cell on April 29, 2021.

"Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases" (https://www.sciencedirect.com/science/article/pii/S0092867421004293)

"Chugai's innovation is generated by its own scientific and technological capabilities. For the maintenance and improvement of state-of-the-art sciences, open innovation including collaboration with academia is essential. I am very proud that one of these efforts to understand disease biology has obtained the world's highest level of scientific appraisal through the publication in Cell," said Dr. Osamu Okuda, Chugai's President and CEO. "TOP I 2030, our growth strategy announced in February, places open innovation as one of its key drivers. We will continue expanding our collaboration with external networks to create innovative new drugs."

This study constructed a large-scale functional genome database "ImmuNexUT" (Immune cell gene expression atlas from the University of Tokyo) that significantly outperforms previous reports in the number of cases of immune-mediated diseases, the variety of clinical cases, and the types of immune cells, and clarified the relationship between gene polymorphisms and gene expression levels in each cell type involved in the onset of various immune-mediated diseases. A total of 9,852 samples of 28 immune cells were obtained from 416 peripheral blood samples from 10 representative patients with immunological diseases and healthy individuals, and these samples were used to quantify gene expression and to analyze the association between gene expression and gene polymorphisms. As valuable data showing the genomic functions of Asians, this database is expected to be applied to genomic studies of various disease states involving immunity, leading to the elucidation of disease states and the identification of therapeutic target molecules and biomarkers for pharmaceuticals.

Chugai participated in this collaborative study with the purpose of elucidating the disease state of autoimmune and autoinflammatory diseases and creating therapies through an integrated understanding of

immunology and functional genomics. In promoting research, Chugai's research subsidiary Forerunner Pharma Research which terminated its operation in March 2021 made significant contributions to building ImmuNexUT through acquisition by utilizing its strong immunology research infrastructure with clinical samples.

Chugai, which aims at becoming a top innovator in the healthcare industry, will promote open innovation including collaboration with academia to contribute to patients around the world through innovative drugs.

###

2 / 2

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 06 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 May 2021 02:34:04 UTC.


ę Publicnow 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD.
04:59aJapan's trade minister unapologetic about ministry's dealings with Toshiba
RE
03:37aToshiba Chairman Apologizes and Deflects Blame for Putting Pressure on Activi..
MT
01:00aPRESS RELEASEá : Roche data at EAN 2021 showcase -3-
DJ
06/14Industrials Pull Back Amid Shift Away From Reopening Stocks -- Industrials Ro..
DJ
06/14CHUGAI PHARMACEUTICALá : Files New Drug Application in Japan for Faricimab, the ..
AQ
06/14Toshiba chair blames ex-CEO for firm's woes
RE
06/14TOSHIBAá : chairman resists calls to resign, to bring in new directors
RE
06/14OSAMU NAGAYAMA : Proxy adviser ISS continues recommendation against appointing T..
RE
06/14Toshiba to Appoint New Directors to Reform Corporate Governance
DJ
06/13Toshiba changes board nominees as two step down in deepening crisis
RE
More news
Financials
Sales 2021 829 B 7 529 M 7 529 M
Net income 2021 244 B 2 219 M 2 219 M
Net cash 2021 451 B 4 098 M 4 098 M
P/E ratio 2021 30,8x
Yield 2021 1,34%
Capitalization 7 488 B 68 012 M 68 016 M
EV / Sales 2021 8,49x
EV / Sales 2022 8,38x
Nbr of Employees 7 555
Free-Float 37,7%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 4 777,69 JPY
Last Close Price 4 555,00 JPY
Spread / Highest target 36,1%
Spread / Average Target 4,89%
Spread / Lowest Target -14,4%
EPS Revisions
Managers and Directors
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-17.23%66 289
JOHNSON & JOHNSON5.08%435 485
ROCHE HOLDING AG10.58%328 513
PFIZER, INC.7.66%221 837
NOVARTIS AG0.23%209 350
ELI LILLY AND COMPANY33.91%205 531